Technical Analysis for IDT - IDT Australia Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gilligan's Island Sell Setup | Bearish Swing Setup | -2.06% | |
| Wide Bands | Range Expansion | -2.06% | |
| Gapped Up | Strength | -2.06% | |
| Upper Bollinger Band Touch | Strength | -2.06% | |
| Calm After Storm | Range Contraction | 5.56% | |
| Narrow Range Bar | Range Contraction | 5.56% | |
| Inside Day | Range Contraction | 5.56% |
| Alert | Time |
|---|---|
| Gilligan's Island Bearish Entry | 4 days ago |
| Fell Below Previous Day's Low | 4 days ago |
| Down 1% | 4 days ago |
| Up 1% | 4 days ago |
| Up 10% | 6 days ago |
Get a Trading Assistant
IDT Australia Limited Description
IDT Australia Limited is engaged in the supply of products and provision of research and development and other technical services for the pharmaceutical and allied industries. The Company's segments include CMAX, Boronia and Corporate/Unallocated. Its CMAX is a clinical trial facility in Adelaide, South Australia. It has an integrated manufacturing, development and corporate facility at Boronia, Victoria. The Company specializes in manufacture of active pharmaceutical ingredients (API) and finished dose products, including beta lactams; microbiological and analytical testing; clinical packaging, and Phase I and first time in man clinical trials research and pharmacy services. Its IDT Pharma specializes in the development, scale-up and current goods manufacturing practices (cGMP) clinical and commercial manufacture of cytotoxic API and finished drug product. The Company also offers a range of clinical trial labelling, packaging and dispensing services.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Manufacturing Pharmaceutical Packaging Clinical Trial Pharmacy Boron Pharmaceuticals Policy Active Pharmaceutical Ingredients Integrated Manufacturing Manufacturing Practice
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.125 |
| 52 Week Low | 0.05 |
| Average Volume | 191,716 |
| 200-Day Moving Average | 0.082 |
| 50-Day Moving Average | 0.088 |
| 20-Day Moving Average | 0.089 |
| 10-Day Moving Average | 0.095 |
| Average True Range | 0.005 |
| RSI (14) | 57.63 |
| ADX | 20.92 |
| +DI | 37.701 |
| -DI | 18.717 |
| Chandelier Exit (Long, 3 ATRs) | 0.089 |
| Chandelier Exit (Short, 3 ATRs) | 0.093 |
| Upper Bollinger Bands | 0.103 |
| Lower Bollinger Band | 0.074 |
| Percent B (%b) | 0.73 |
| BandWidth | 32.542 |
| MACD Line | 0.003 |
| MACD Signal Line | 0.002 |
| MACD Histogram | 0.0008 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.095 | ||||
| Resistance 3 (R3) | 0.095 | 0.095 | 0.095 | ||
| Resistance 2 (R2) | 0.095 | 0.095 | 0.095 | 0.095 | |
| Resistance 1 (R1) | 0.095 | 0.095 | 0.095 | 0.095 | 0.095 |
| Pivot Point | 0.095 | 0.095 | 0.095 | 0.095 | 0.095 |
| Support 1 (S1) | 0.095 | 0.095 | 0.095 | 0.095 | 0.095 |
| Support 2 (S2) | 0.095 | 0.095 | 0.095 | 0.095 | |
| Support 3 (S3) | 0.095 | 0.095 | 0.095 | ||
| Support 4 (S4) | 0.095 |
